Immunotherapy + Radiation for Lung Cancer

Recruiting in Palo Alto (17 mi)

Overseen byAnne S Tsao

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This phase I trial studies the side effects of ipilimumab and nivolumab in combination with radiation therapy, and to see how well they work in treating patients with stage II-III non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Ipilimumab and nivolumab may also help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Giving ipilimumab and nivolumab in combination with radiation therapy may work better in treating patients with stage II-III non-small cell lung cancer compared to standard chemotherapy in combination with radiation therapy.

Eligibility Criteria

This trial is for adults with stage II-III non-small cell lung cancer that can't be removed by surgery or patients who refuse surgery. They must have a good performance status, meaning they're fairly active and able to care for themselves. People with certain stable autoimmune conditions or controlled diabetes may join. However, those with recent other cancers, severe allergies to similar drugs, untreated infections like TB or hepatitis, HIV, or on immunosuppressive therapy cannot participate.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document

My cancer has an EGFR mutation or ALK rearrangement.

You have enough white blood cells called neutrophils.

See 16 more

Exclusion Criteria

You have had strong allergic reactions to certain types of medications made from antibodies or fusion proteins.

Pregnant women

I am HIV positive.

See 10 more

Treatment Details

Interventions

Ipilimumab (Checkpoint Inhibitor)
Nivolumab (Checkpoint Inhibitor)
Radiation Therapy (Radiation)

Trial OverviewThe trial tests the combination of two immune system-boosting drugs (Ipilimumab and Nivolumab) with radiation therapy against lung cancer. The goal is to see if this combo helps the body's own defense system fight cancer better and makes tumor cells more sensitive to radiation compared to standard chemotherapy plus radiation.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (nivolumab, ipilimumab, radiation therapy)Experimental Treatment3 Interventions

CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Ipilimumab is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Yervoy for: